While it is noted as a risk-enhancing factor in AHA/ACC Cholesterol Guidelines,18 there is a need for clearer guidance on apolipoprotein B (ApoB) testing, given its critical role in the pathophysiology of ASCVD and as a risk factor, especially in patients with metabolic syndrome and high levels of triglycerides. Here, APOB is linked to metabolic syndrome.